Supernus Pharmaceuticals (SUPN) PT Raised to $40 at Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts SUPN Hot Sheet
Price: $40.96 +0.47%
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 18
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 18
Join SI Premium – FREE
Cowen analyst Ken Cacciatore raised the price target on Supernus Pharmaceuticals (NASDAQ: SUPN) to $40.00 (from $35.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Applied Industrial Technologies (AIT) PT Lowered to $360 at KeyBanc
- FireFly Metals Ltd (FFM:AU) PT Raised to AUD3.60 at Canaccord
- Sandfire Resources NL (SFR:AU) (SNDFY) PT Lowered to AUD25 at Canaccord
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
